SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guidant (GDT) -- Ignore unavailable to you. Want to Upgrade?

To: gan who wrote (81)1/23/1998 11:38:00 PM
From: jbershad  Read Replies (1) | Respond to of 235
 
There are some products that do not directly
compete with BSX.(i.e. EVT products) I think
problem might be introductions of many new product
approvals. From what I read GDT has edge and lead
in most. Not in medical field but have numerous
reports. Zacks rates GDT higher than BSX. Price action
for GDT poor today while BSX good. I think it means nothing.
Could be EVTI shareholders selling after merger.
Who knows?

Jerry

P.S. I own both stocks.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News